Drug
Valemetostat clinical trials
Also written DS-3201.
Includes 10 studies of Valemetostat tosylate.
- studies test it
- 16
- open now
- 5
- in phase 3
- 0
- first study started
- 2016
Keep track of what changes. Save the valemetostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
16 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 9
Daiichi Sankyo (5) · M.D. Anderson Cancer Center (2) · Daiichi Sankyo Co., Ltd. (2) · Memorial Sloan Kettering Cancer Center (2) · The Lymphoma Academic Research Organisation (1) · Alliance for Clinical Trials in Oncology (1) · University of Alabama at Birmingham (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
Often tested with
Tested in the same studies.
Atezolizumab (2) · Rituximab (1) · Lenalidomide (1) · Ipilimumab (1) · Carboplatin (1) · Cabazitaxel (1) · Abiraterone Acetate (1) · Abiraterone (1)
Studies
Open first, then newest update. How each study uses valemetostat is read from its arms, and is right about nine times in ten.
Testing it · 16
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Valemetostat Tosylate
- A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCCRecruitingPhase 1/2University of Alabama at BirminghamNCT06294548Written as Valemetostat
- A Study of Valemetostat in Combination With Atezolizumab in People With Lung CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT06807632Written as Valemetostat
- A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)RecruitingPhase 1Daiichi SankyoNCT07244341Written as Valemetostat
- Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.RecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07303387Written as Valemetostat Tosylate
- A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsActive, not recruitingPhase 1/2Daiichi SankyoNCT06644768Written as valemetostat tosylate
- Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)Active, not recruitingPhase 2Daiichi SankyoNCT04703192Written as Valemetostat Tosylate
- A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT05683171Written as Valemetostat
- DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT04388852Written as Valemetostat
- DS-3201b in Participants With LymphomasActive, not recruitingPhase 1Daiichi Sankyo Co., Ltd.NCT02732275Written as DS-3201b
- Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell LymphomaActive, not recruitingPhase 2The Lymphoma Academic Research OrganisationNCT04842877Written as Valemetostat tosylate
- Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASWithdrawnPhase 1/2National Cancer Institute (NCI)NCT05879484Written as valemetostat
- Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/LymphomaCompletedPhase 2Daiichi Sankyo Co., Ltd.NCT04102150Written as Valemetostat Tosylate
- DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung CancerTerminatedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT03879798Written as DS-3201b
- DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)TerminatedPhase 1Daiichi SankyoNCT03110354Written as DS-3201b
- Study of Single-dose DS-3201b in Participants With Hepatic ImpairmentCompletedPhase 1Daiichi SankyoNCT04276662Written as DS-3201b
Given in every arm · 3 — valemetostat is usual care beside what is tested
- A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid TumorsActive, not recruitingPhase 1Daiichi SankyoNCT06244485Written as Valemetostat tosylate
- Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT05633979Written as Valemetostat
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruitingPhase 1/2CelgeneNCT03930953Written as Valemetostat
Codes
What other systems call valemetostat · ClinicalTrials.gg INT015161
- UNII (FDA) 60RD0234VEVALEMETOSTATOne source FDA
- NCI Thesaurus C127114ValemetostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 60RD0234VE | VALEMETOSTAT | One source FDA |
| NCI Thesaurus | C127114 | Valemetostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.